🙌🏼More flexible PrEP regimens may improve access and adherence, particularly crucial for reaching underserved or hard-to-reach populations in HIV prevention efforts.

www.immedicohospitalario.es/noticia/5250...

💬 Is a rollout justified with 30% efficacy?
In a context of rising resistance and no alternative vaccine candidates, this might be a reasonable public health decision.

📍The NHS will pilot this strategy in MSM with recent STI or multiple sexual partners.

#Gonorrhea #Vaccines #AMR #STIs #MenB

Following FDA approval of lenacapavir for HIV PrEP, the IAS-USA panel has released an updated brief of its 2024 recommendations.
🔹 LEN for all populations
🔹 TAF/FTC for cisgender women

🔥These updates mark an important shift in the PrEP landscape.

#PrEP #HIV #Lenacapavir #TAF

Thanks to all patients, collaborating centers, and investigators involved in this effort.

Full text here 👇🏼👇🏼
sciencedirect.com/science/articl…

@gesida-seimc.bsky.social @GEHEP @seimc.bsky.social @CIBERINFEC

These results suggest a slower fibrosis regression in PLWH, potentially translating into a persistent risk of liver-related complications, even after HCV eradication.

#HCV #HIV #HepatitisC

After propensity score matching and competing risks modeling (death as competing event), HIV co-infection was independently associated with reduced probability of LS normalization:

37% in HCV vs. 32% in HIV/HCV (p = 0.003)

Adjusted sub-HR = 0.76 (95% CI: 0.56–0.97).

Thank you very much to all the participants🙏🏼

@GEHEP @Evirologia @ofidjournal.bsky.social
#HIVSky #HCVSky

Curious about long-term outcomes after DAA therapy?
This one's for you!
Share & discuss 🔁 🧠

🇪🇦 GEHEP-011

Main findings:
• ⏳ Follow-up: median 6 years
• 12%liver events (5% HCC)
• 📊 Diagnostic performance: LS had better accuracy (AUROC 0.83 vs 0.80)
• ✅ LS <14 kPa identified 52% as low risk, missing only 3 events (1.9%)
• ✅ FAST ≤0.35 identified 59% as low risk, but missed 6 events (3.3%)